Across TCGA pan-cancer cohorts, SEMA3G mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SEMA3G data layer compared with 21 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SEMA3G mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEMA3G expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
LUAD and LSCC are the cancer types where SEMA3G mass-spec protein most reproducibly stratifies survival.